Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYXPF8)

Drug Name

QO-58 Drug Info

Synonyms

CHEMBL1689654; QO-58; GTPL7669; SCHEMBL10062354; MolPort-042-624-524; QO 58; BDBM50339281; ZINC101404854; AKOS027470159; 1259536-62-3; 5-(2,6-Dichloro-5-fluoro-3-pyridinyl)-3-phenyl-2-(trifluoromethyl)-pyrazolo[1,5-a]pyrimidin-7(4H)-one; 5-(2,6-Dichloro-5-fluoropyridin-3-yl)-3-phenyl-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 51351551
TTD Drug ID: DMYXPF8

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated potassium channel Kv7.2 (KCNQ2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ICA-69673	DM1RZVI	Pain	MG30-MG3Z	Preclinical	[3]
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[4]
PIP2	DMOZV7N	Discovery agent	N.A.	Investigative	[5]
PD-32577	DMBA15J	Discovery agent	N.A.	Investigative	[6]
zinc pyrithione	DMF0CRA	Discovery agent	N.A.	Investigative	[7]
XE991	DMLH1PK	Discovery agent	N.A.	Investigative	[8]
(S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide	DMGFOQJ	Discovery agent	N.A.	Investigative	[9]
ICA-27243	DMO0N3Q	Discovery agent	N.A.	Investigative	[10]
ztz240	DM60N3C	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated potassium channel Kv7.2 (KCNQ2)	TTPXI3S	KCNQ2_HUMAN	Activator	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7669).
2	Modulation of K(v)7 potassium channels by a novel opener pyrazolo[1,5-a]pyrimidin-7(4H)-one compound QO-58. Br J Pharmacol. 2013 Feb;168(4):1030-42.
3	Voltage-gated Potassium Channels as Therapeutic Drug Targets
4	Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol. 2000 Sep;58(3):591-600.
5	Regulation of Kv7 (KCNQ) K+ channel open probability by phosphatidylinositol 4,5-bisphosphate. J Neurosci. 2005 Oct 26;25(43):9825-35.
6	Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
7	Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007 May;3(5):287-96.
8	KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science. 1998 Dec 4;282(5395):1890-3.
9	The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology. 2006 Nov;51(6):1068-77.
10	The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site. Neurosci Lett. 2009 Nov 13;465(2):138-42.
11	Isoform-specific prolongation of Kv7 (KCNQ) potassium channel opening mediated by new molecular determinants for drug-channel interactions. J Biol Chem. 2010 Sep 3;285(36):28322-32.